Advisory Board and Editors Pharmacology
Haseeb A. Khan
Distinguished Professor of Biochemistry at College of Science, King Saud University, Riyadh, Saudi Arabia. Group Leader of Analytical and Molecular Bioscience Research Group and a Chair Professor at Research Chair for Biomedical Applications of Nanomaterials, King Saud University. PhD from Aligarh Muslim University, Aligarh, India and received scientific trainings in USA, UK, Denmark and Finland. Fellow of the Royal College of Pathologists (FRCPath) and the Royal Society of Chemistry (FRSC), UK. Authored more than 300 publications including 2 books and 20 book chapters. Recipient of Microsoft eScience Award. Listed in Top-2% World Ranking of Scientists. Research interests are clinical biochemistry, analytical chemistry, environmental chemistry, nanobiotechnology, molecular conservation, bioinformatics, pharmacology, and toxicology.
Mei-Chuan Ko
Professor in the Department of Psychiatry, University of Pittsburgh School of Medicine. My research interests involve behavioral neuropharmacology of pain and addiction, including 1) biological basis and pharmacotherapy for drug abuse and dependence and 2) neuropharmacological basis of therapeutics of analgesics and antipruritics.
Hang Fai Kwok
Prof Kwok’s research interests mainly focus on the development of novel monoclonal antibodies and venom-based peptides as prototype drugs for anticancer and anti-inflammatory therapies. In addition, Prof. Kwok’s research group is also expanding scientific knowledge and research in the areas of existing and novel cancer biomarkers such as 1) matricellular protein — OPN, 2) metalloproteinase — ADAM17 & ADAMTS5, 3) DNA replication licensing factor — MCM proteins, 4) small GTP binding protein — RAN, as well as immunotherapy markers (e.g. PD-1/PD-L1) in order to identify and validate their prognostic and therapeutic values according to the roles in hallmarks of cancer.
Dirk W. Lachenmeier
Dr. Dirk Lachenmeier is a state-certified food chemist, toxicologist, head of the department of plant-based foods and co-head of the nuclear magnetic resonance laboratory at Chemical and Veterinary Investigation Agency, Karlsruhe, Germany, which is a governmental food, medicine and alcohol control authority.
He earned his PhD in Forensic Toxicology from the University of Bonn.
Brittany N Lasseigne
Brittany N. Lasseigne, PhD is an Assistant Professor of Cell, Developmental and Integrative Biology at The University of Alabama at Birmingham School of Medicine. She trained in Biotechnology, Science, and Engineering at Mississippi State University (B.S.) and the University of Alabama in Huntsville (Ph.D.) and completed a postdoctoral fellowship in genetics and genomics at the HudsonAlpha Institute for Biotechnology.
Her lab develops and applies genomic- and data-driven strategies (including single-cell and long-read sequencing) to discover biological signatures that might be used to improve patient care and provide insight into the cellular and molecular processes contributing to disease, especially for diseases impacting the brain and/or kidney. Their recent work includes prioritizing drug repurposing candidates for cancers and polycystic kidney disease, evaluating preclinical models and cross-species transcriptomic signatures to improve disease modeling, and applying single-cell and long-read technologies to neurological disease tissues to understand the role that context plays in disease etiology, progression, and treatment.
The Lasseigne Lab is currently focused on integrating genomics data, functional annotations, and patient information with machine learning and regulatory network approaches across diseases that impact the brain or kidney to discover novel mechanisms in disease etiology and progression, identify genome-driven therapeutic targets and opportunities for drug repositioning and repurposing, determine clinically-relevant biomarkers, and understand how cellular context contributes to these diseases. Collectively, these distinct projects all apply genetics and genomics to human diseases and build tools to accelerate future research. Their lab also develops data science software and analytical pipelines that are open-source, well-documented, and hosted by third-party code distributors, critical for facilitating reproducibility and enabling the research community to use the methods they develop.
Florian Lesage
Florian Lesage is senior research director at INSERM (French National Health Institute). He is a molecular biologist with extensive experience in ion channel cloning, expression and characterization, in particular in the neurosensory systems. He has authored 15 international patents and >120 publications that have received more than 15,000 citations (http://scholar.google.fr/citations?user=4RXbfuMAAAAJ&hl=fr&oi=ao).
Florian Lesage is the director of the Laboratoire d'Excellence "Ion Channel Science and Therapeutics" (LabEx ICST, www.labex-icst.fr/en).
Dongliang Liu
Dr. Dongliang Liu is a Postdoctoral Associate in the Department of Surgery at the Baylor College of Medicine. His research interests include: Cancer therapy, especially for pancreatic cancer immunotherapy; Chimeric virus-like particles (VLP) vaccine, especially for cancer vaccines; Novel antibiotics development including antimicrobial peptides; Epitomics and multi-epitope peptide vaccine development for pathogenic viruses.
Yoshinori Marunaka
Prof. Marunaka is the President and the Representative Director, Director of Clinical, and Director of Medical Research Institute, Kyoto Industrial Health Association; Professor, Research Organization of Science and Technology, Ritsumeikan University; Professor Emeritus, Kyoto Prefectural University of Medicine; Former President, Physiological Society of Japan. Former President, International Society of Cancer Metabolism. MD (1979), PhD (1985), Kyoto Prefectural University of Medicine; National License of Physician and Surgeon, Japan (1979). He was Professor and Chairperson, Departments of Molecular Cell Physiology and Bio-Ionomics, Kyoto Prefectural University of Medicine, Japan, and Director and Professor, Japan Institute for Food Education and Health, St. Agnes’ University. He was awarded “Vebleo Nanomedicine Scientist Award” (Sweden), “Marco Polo della Scienza Italiana” (Italy), The Premier's Research Excellence Award (Canada), Scholar Award (Medical Research Council of Canada) and Research Award from National Kidney Foundation of USA. He has obtained more than 60 research grants, published more than 270 peer reviewed articles, and provided more than 30 invited plenary lectures at international congresses and research conferences. h-index 47, i10-index 190, Citation 7498
Fabrizio Mattei
Dr. Fabrizio Mattei graduated from University “La Sapienza” in Rome and completed his specialization in biotechnologies and oncology at the same university. In 2000, he became a fellow at the Edward Jenner Institute for Vaccine Research in David Tough's laboratory (Newbury, U.K.), where he acquired experience in the field of dendritic cell immunology. He is currently a Researcher, Group Leader and Principal Investigator at the Istituto Superiore di Sanità (Rome, Italy), where he has focused on the molecular interactions between dendritic cells and type I Interferons signalling.
His current research is aimed at understanding the role of Interferons signalling and IL-33 in the interface between tumor and immune system in both mouse and human models. Furthermore, he is also conducting research aimed at investigating on crosstalk between immune system and cancer by Cell-on-Chip devices. In addition, Dr. Mattei is developing a multidisciplinary laboratory network focused at the realization of Organ-On-Chip platforms, useful to mimic and study human diseases and cancer.
Ipsita Mohanty
Dr. Ipsita Mohanty is a Research Associate II at the Children's Hospital of Philadelphia Research Institute
Her current research focuses on investigating the molecular mechanisms of nitric oxide signaling pathway at the proteome levels using multipronged approach of mouse genetics, ex vivo mechanistic functional study as well as high throughput mass spectroscopy techniques.
Dr. Mohanty has expertise in pharmacology, physiology, and proteomics with emphasis in intracellular signal transduction and GPCR signaling directed towards designing therapeutic strategies for cardiovascular disorders. Technical cognizance encompasses fields of Smooth Muscle pharmacology, Integrative Physiology, Contraction Physiology, Proteomics, Biochemistry, Molecular Biology, Bioinformatic Data Analysis (and related softwares) for Mass Spectrometry data and In-Vivo skills.
Rafael J Najmanovich
Associate Professor, Systems & Structural Computational Pharmacology. University of Montreal, Canada. Postdoc EMBL-EBI. PhD Physics & Biology, Weizmann Institute of Science, Israel. MSc Statistical Biological Physics & BSc. Molecular Sciences, University of São Paulo, Brazil.
Giribabu Nelli
Dr. Giribabu Nelli is a Senior Lecturer within the Department of Physiology at Universiti Malaya.
Hi primary research areas include, Reproductive Biology, Diabetes and their complications, and Natural Products Research.